The role of phosphodiesterases in schizophrenia: Therapeutic implications

CNS Drugs

Volumn 22, Issue 12, 2008, Pages 983-993

  Siuciak, Judith A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Papaverine, pharmacodynamics; Phosphodiesterase 10A inhibitors, therapeutic use; Phosphoric diester hydrolase inhibitors, therapeutic use; Research and development; Rolipram, pharmacodynamics; Rolipram, therapeutic use; Schizophrenia, treatment

Indexed keywords

BAY 60 7550; CLOZAPINE; CYCLIC AMP; CYCLIC GMP; DESIPRAMINE; FLUOXETINE; MEM 1414; MEM 1917; MK 0952; PAPAVERINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MAPPING; GENE SEQUENCE; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SYMPTOM;

ANIMALS; ANTIPSYCHOTIC AGENTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; MICE; MICE, KNOCKOUT; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SCHIZOPHRENIA;

EID: 55949132109     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/0023210-200822120-00002     Document Type: Review

References (110)

1. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005; 1: 27-39
2. Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007; 10: 904-22
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353: 1209-23
4. Beavo JA, Houslay MD, Francis SH. Cyclic nucleotide phosphodiesterase superfamily. In: Beavo JA, Francis SH, Houslay MD, editors. Cyclic nucleotide phosphodiesterases in health and disease. Boca Raton (FL): CRC Press, 2007: 3-17
5. Lungier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-98
6. Conti M, Richter W, Mehats C, et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003; 8: 5493-6
7. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005; 10: 1503-19
8. Lobban M, Shakur Y, Beattie J, et al. Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochem J 1994; 304: 399-406
9. McPhee I, Pooley L, Lobban M, et al. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem J 1995; 310: 965-74
10. Iona S, Cuomo M, Bushnik T, et al. Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain. Mol Pharmacol 1998; 53: 23-32
11. Cherry JA, Davis RL. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 1999; 407: 287-301
12. Perez-Torres S, Miro X, Palacios JM, et al. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography: comparison with monkey and rat brain. J Chem Neuroanat 2000; 20: 349-74
13. Graybiel AM. The basal ganglia. Curr Biol 2000; 10: R509-12
14. Engels P, Abdel'Al S, Hulley P, et al. Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. J Neurosci Res 1995; 41: 169-78
15. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 1983; 22: 267-72
16. Wachtel H. Species differences in behavioural effects of rolipram and other adenosine cyclic 3H, 5H-monophosphate phosphodiesterase inhibitors. J Neural Transm 1983; 56: 139-52
17. Schneider HH. Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem Pharmacol 1984; 33: 1690-3
18. MacKenzie SJ, Houslay M. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element- binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J 2000; 347: 571-8
19. Robichaud A, Stamatiou PB, Jin SL, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002; 110: 1045-52
20. Jin S-LC, Richard FJ, Kuo WP, et al. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci U S A 1999; 96: 11998-2003
21. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 2002; 99: 7628-33
22. Jin SL, Latour AM, Conti M. Generation of PDE4 knockout mice by gene targeting. Methods Mol Biol 2005; 307: 191-210
23. Siuciak JA, Chapin DS, McCarthy SA, et al. Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology 2007; 192: 415-24
24. Siuciak JA, McCarthy SA, Chapin DS, et al. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl) 2008; 197: 115-26
25. Zhang HT, Huang Y, Jin SL, et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 2002; 27: 587-95
26. Zhang HT, Huang Y, Masood A, et al. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 2008; 33: 1611-23
27. Chapin DS, McCarthy SA, Martin AN, et al. Rolipram, a PDE4 inhibitor, shows efficacy in animal models of antipsychotic-like activity: studies using PDE4B and PDE4D knockout mice [abstract]. Schizophr Bull 2007; 33: 470
28. Siuciak JA, McCarthy SA, Chapin DS, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 2006; 51: 374-85
29. Siuciak JA, McCarthy SA, Chapin DS, et al. Behavioral characterization of mice deficient in the phosphodiesterase-10 (PDE10A) enzyme on a C57/BL6N congenic background. Neuropharmacology 2008; 54: 417-27
30. Reed TM, Browning JE, Blough RI, et al. Genomic structure and chromosome location of the murine PDE1B phosphodiesterase gene. Mamm Genome 1998; 9: 571-6
31. Ehrman LA, Williams MT, Schaefer TL, et al. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice. Genes Brain Behav 2006; 5: 540-51
32. Siuciak JA, McCarthy SA, Chapin DS, et al. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology 2007; 53: 113-24
33. Millar JK, Pickard BS, Mackie S, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 2005; 31: 1187-91
34. Pickard BS, Thomson PA, Christoforou A, et al. The PDE4B gene confers sex-specific protection against schizophrenia. Psychiatr Genet 2007; 17: 129-33
35. Clapcote SJ, Lipina TV, Millar JK, et al. Behavioral phenotypes of DISC1 missense mutations in mice. Neuron 2007; 54: 387-402
36. Mori T, Baba J, Ichimaru Y, et al. Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice. Jpn J Pharmacol 2000; 83: 113-8
37. Maxwell CR, Kanes SJ, Abel T, et al. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 2004; 129: 101-7
38. Kanes SJ, Tokarczyk J, Siegel SJ, et al. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007; 144: 239-46
39. Davis JA, Gould TJ. Rolipram attenuates MK-801-induced defiscits in latent inhibition. Behav Neurosci 2005; 119: 595-602
40. Becker A, Grecksch G. Phosphodiesterase inhibitors, are they potential neuroleptic drugs? Behav Brain Res 2008; 186: 155-60
41. Wadenberg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 1999; 23 (6): 851-62
42. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160 (1): 13-23
43. Pietzcker A, Muller-Oerlinghausen B, Kehr W. Antipsychotic activity of rolipram in schizophrenic patients: pilot study [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1979; 308: R44
44. Rose GM, Hopper A, De Vivo M, et al. Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 2005; 11: 3329-34
45. Blokland A, Schreiber R, Prickaerts J. Improving memory: a role for phosphodiesterases. Curr Pharm Des 2006; 12: 2511-23
46. Bourtchouladze R, Lidge R, Catapano R, et al. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci U S A 2003; 100: 10518-22
47. Rutten K, Prickaerts J, Blokland A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol Learn Mem 2006; 85: 132-8
48. Rutten K, Prickaerts J, Hendrix M, et al. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 2007; 558: 107-12
49. Rutten K, Lieben C, Smits L, et al. The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology (Berl) 2007; 192: 275-82
50. Egawa T, Mishima K, Matsumoto Y, et al. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn J Pharmacol 1997; 75: 275-81
51. Imanish T, Sawa A, Ichimaru Y, et al. Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur J Pharmacol 1997; 321: 273-8
52. Ghelardini C, Galeotti N, Gualtieri F, et al. DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 419-26
53. Zhang HT, Huang Y, Suvarna NU, et al. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berl) 2005; 179: 613-9
54. Zhang HT, O'Donnell JM. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology 2000; 150: 311-6
55. Zhang HT, Crissman AM, Dorairaj NR, et al. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 2000; 23: 198-204
56. Gong B, Vitolo OV, Trinchese F, et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004; 114 (11): 1624-34
57. Nagakura A, Niimura M, Takeo S. Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats. Br J Pharmacol 2002; 135: 1783-93
58. Barad M, Bourtchouladze R, Winder DG, et al. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci U S A 1998; 95: 15020-5
59. Nguyen T, Lewis SR, Moschak TM, et al. Cognitive enhancing and antipsychotic effects of phosphodiesterase inhibitors. 2007 Neuroscience Meeting Planner, Society for Neuroscience; 2007 Nov 3-7; San Diego (CA) [online]. Available from URL: http://www.sfn.org/index.cfm?pagename= abstracts_ampublications§ion=publications [Accessed 2008 Oct 28]
60. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201-25
61. Memory Pharmaceuticals Corp. Memory Pharmaceuticals development pipeline [online]. Available from URL: http://www.memorypharma.com/pipe.html [Accessed 2008 Sep 1]
62. MK0952 in patients with mild-to-moderate Alzheimer's disease [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00362024 [Accessed 2008 Sep 8]
63. Mouri A, Noda Y, Enomoto T, et al. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 2007; 51 (2-4): 173-84
64. Renau TE. The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Curr Opin Investig Drugs 2004; 5: 34-9
65. O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004; 25: 158-63
66. Saccomano NA, Vinick FJ, Koe BK, et al. Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)- 4-methoxyphenyl]-2-imidazolidinones. J Med Chem 1991; 34: 291-8
67. Itoh T, Tokumura M, Abe K. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. Eur J Pharmacol 2004; 498: 135-42
68. Mizokawa T, Kimura K, Ikoma Y, et al. The effect of a selective phosphodiesterase inhibitor, rolipram, on muricide in olfactory bulbectomized rats. Jpn J Pharmacol 1988; 48: 357-64
69. O'Donnell JM. Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther 1993; 264: 1168-78
70. Overstreet DH, Double K, Schiller GD. Antidepressant effects of rolipram in a genetic animal model of depression: cholinergic supersensitivity and weight gain. Pharmacol Biochem Behav 1989; 34: 691-6
71. Bertolino A, Crippa D, di Dio S, et al. Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 1988; 3: 245-53
72. Fleischhacker WW, Hinterhuber H, Bauer H, et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 1992; 26: 59-64
73. Hebenstreit GF, Fellerer K, Fichte K, et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 1989; 22: 156-60
74. Scott AI, Perini AF, Shering PA, et al. In-patient major depression: is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 1991; 40: 127-9
75. Zeller E, Stief HJ, Pflug B, et al. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984; 17: 188-90
76. Ye Y, Conti M, Houslay MD, et al. Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem 1997; 69: 2397-404
77. Takahashi M, Terwilliger R, Lane S, et al. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci 1999; 19: 610-8
78. Dlaboga D, Hajjhussein H, O'Donnell JM. Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram. Brain Res 2006; 1096: 104-12
79. Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Nat Acad Sci U S A 1999; 96: 7071-6
80. Loughney K, Snyder PB, Uher L, et al. Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene 1999; 234: 109-17
81. Fujishige K, Kotera J, Michibata H, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 1999; 274: 18438-45
82. Fujishige K, Kotera J, Omori K. Striatum- and testis-specific phosphodiesterase PDE10A: isolation and characterization of a rat PDE10A. Eur J Biochem 1999; 266: 1118-27
83. Kotera J, Fujishige K, Yuasa K, et al. Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Biochem Biophys Res Commun 1999; 261: 551-7
84. Hu H, McCaw EA, Hebb ALO, et al. Mutant huntintin affects the rat of transcription of striatum-specificisoforms of phosphodiesterase 10A. Eur J Neurosci 2004; 20: 3351-63
85. O'Connor V, Genin A, Davis S, et al. Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific PDE10A phosphodiesterase splice variants. J Biol Chem 2004; 279: 15841-9
86. Seeger TF, Bartlett B, Coskran TM, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res 2003; 985: 113-26
87. Xie Z, Adamowicz WO, Eldred WD, et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 2006; 139: 597-607
88. Coskran TM, Morton D, Adamowicz WO, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006; 54: 1205-13
89. Siuciak JA, Chapin DS, Harms JF, et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006; 51: 386-96
90. Siuciak JA, Chapin DS, McCarthy SA, et al. Novel potent and selective phosphodiesterase 10A (PDE10A) inhibitors show activity in animal models of psychosis. Neuroscience Meeting Planner, Society for Neuroscience; 2006 Oct 11-18; Atlanta (GA) [online]. Available from URL: http://www.sfn.org/index.cfm? pagename=abstracts_ampublications§ion=publications [Accessed 2008 Oct 28]
91. Siuciak JA, Chapin DS, McCarthy SA, et al. Novel potent and selective PDE10A inhibitors show activity in animal models of psychosis and anxiety [abstract]. Schizophr Bull 2007; 33: 479
92. Chappie TA, Humphrey JM, Allen MP, et al. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J Med Chem 2007; 50: 182-5
93. Schmidt CJ, Chapin DS, Cianfrogna J, et al. A new therapeutic approach to the treatment of schizophrenia: preclinical characterization of selective PDE10A inhibitors. J Pharmacol Exp Ther 2008; 325: 681-90
94. Lindholm E, Ekholm B, Shaw S, et al. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. Am J Hum Genet 2001; 69: 96-105
95. Rodefer JS, Murphy ER. Baxter MG. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 2005; 21: 1070-6
96. Liu F, Zhang G, Kelley C, et al. Biochemical analysis of mechanism action of PDE10A inhibitor papaverine in procognitive effects. Neuroscience Meeting Planner, Society for Neuroscience; 2006 Oct 11-18; Atlanta (GA) [online]. Available from URL: http://www.sfn.org/index.cfm?pagename= abstracts_ampublications§ion=publications [Accessed 2008 Oct 28].
97. Hebb AL, Robertson HA, Denovan-Wright EM. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice. Eur Neuropsychopharmacology 2008; 18: 339-63
98. Cole JO, Branconnier RJ, Martin GF. Electroencephalographic and behavioral changes associated with papaverine administration in healthy geriatric subjects. J Am Geriatr Soc 1975; 23 (7): 295-300
99. Nelson JJ. Relieving select symptoms of the elderly. Geriatrics 1975; 30 (3): 133-9, 142
100. Yesavage JA, Tinklenberg JR, Hollister LE, et al. Vasodilators in senile dementias: a review of the literature. Arch Gen Psychiatry 1979; 36 (2): 220-3
101. Smith WL, Philippus MJ, Lowrey JB. A comparison of psychological and psychophysical test patterns before and after reproach ceiving papaverine HCL. Curr Ther Res Clin Exp 1968; 10 (9): 428-31
102. Polli JW, Kincaid RL. Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum. Proc Natl Acad Sci U S A 1992; 89: 11079-83
103. Yan C, Bentley JK, Sonnenburg WK, et al. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J Neurosci 1994; 14: 973-84
104. Van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, et al. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 2003; 467: 566-80
105. Juilfs DM, Soderling S, Burns F, et al. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem 1999; 135: 67-104
106. Cho CH, Cho DH, Seo MR, et al. Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp Mol Med 2000; 32: 110-4
107. Sasaki T, Kotera J, Omori K. Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochemical J 2002; 361: 211-20
108. Reyes-Irisarri E, Perez-Torres S, Mengod G. Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 2005; 132: 1173-85
109. Boess FG, Hendrix M, van der Staay FJ, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004; 47: 1081-92
110. Rutten K, Prickaerts J, Steinbusch H, et al. Inhibitors of PDE2, PDE4 and PDE5 enhance spatial memory in a time-dependent manner in the object location task in rats. 2007 Neuroscience Meeting Planner, Society for Neuroscience; 2007 Nov 3-7; San Diego (CA) [online]. Available from URL: http://www.sfn.org/index. cfm?pagename=abstracts_ampublications§ion=publications [Accessed 2008 Oct 28]